1051375-10-0

1051375-10-0 structure

Name: Cabotegravir
Chemical Name: SureCN82803
CAS Number: 1051375-10-0
Molecular Formula: C₁₉H₁₇F₂N₃O₅
Molecular Weight: 405.352
Catalog: Biochemical Inhibitor Microbiology Integrase inhibitor
Create Date: 2018-09-17 16:30:13
Modify Date: 2026-07-08 17:59:50
Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. Cabotegravir is an inhibitor of OAT1 (IC50 0.81 μM) and OAT3 (IC50 0.41 μM).IC50 value: 0.81 μM (OAT1), 0.41 μM (OAT3) [1]Target: OAT1, OAT3Cabotegravir is a potent HIV integrase inhibitor in clinical development as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.[2] Cabotegravir is an HIV-1 integrase inhibitor under development as a tablet for both oral lead-in therapy and long-acting (LA) injectable for intramuscular dosing.[3]

Name	SureCN82803
Synonyms	Caboteavir ,GSK744 S/GSK1265744 Cabotewei Caboteavir Caboteavir, 10 mM in DMSO Caboteavin (3S,11aR)-N-(2,4-Difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide Caboteve Cyclic pyranopterin (3S,11-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2 Caboteavir Free Acid Caboteavir(GSK1265744A,GSK-744) SK744, GSK1265744 (3S,11-N-[(2,4-Difluorophenyl)methyl]-2,3,5,7,11,11a-hexa (3S,11-N-(2,4-DIFLUOROBENZYL)-6-HYDROXY-3-METHYL-5,7-DIOXO-2,3,5,7,11,11A-HEXAHYDROOXAZOLO[3,2-A]PYRIDO[1,2-D]PYRAZINE-8-CBOXAMIDE 13C,2H2,15N]-Caboteavir Caboteavir (GSK744, GSK1265744) (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-cboxamide Caboteavir GSK744 GSK1265744 GSK-744 GSK1265744 GSK744 Caboteavir (GSK-1265744） Caboteavir 13CD5 Caboteavir (GSK744, GSK1265744) //BP GSK1265744A GSK744 (S/GSK1265744) unii-hmh0132z1q Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-cboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11) Cabotwe (3S,11-N-[(2,4-Difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-cboxamide Cabot wei

Description	Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. Cabotegravir is an inhibitor of OAT1 (IC50 0.81 μM) and OAT3 (IC50 0.41 μM).IC50 value: 0.81 μM (OAT1), 0.41 μM (OAT3) [1]Target: OAT1, OAT3Cabotegravir is a potent HIV integrase inhibitor in clinical development as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.[2] Cabotegravir is an HIV-1 integrase inhibitor under development as a tablet for both oral lead-in therapy and long-acting (LA) injectable for intramuscular dosing.[3]
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> HIV Integrase Signaling Pathways >> Anti-infection >> HIV Research Areas >> Infection
References	[1]. Reese MJ, Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12. [2]. Reese MJ, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12. [3]. Bowers GD, Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2015 Jul 1:1-16.